|
Retargetable and Metabolically Tunable CAR Cell Platforms for Durable, Antigen‑Specific Cancer Therapy
SHORT DESCRIPTION
A modular immunotherapy platform that combines hapten‑redirectable chimeric antigen receptor (CAR) constructs with itaconate‑programmed, memory‑like immune cells to deliver safer, more durable, and tunable antigen‑specific responses across hematologic and solid tumors.
NU TECH ID
NU 2023-021, NU 2024-077
INVENTORS
Ashima...
Published: 6/10/2026
|
Updated: 6/10/2026
|
Inventor(s):
Keywords(s): Autoimmune disease, Cancer Treatment, Cancer/Oncology, Cell therapy, Immunology, Immunotherapy, Inflammation, Leukemia, Lymphoma, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Small Molecule Inhibitors of Pleckstrin-2 for Treating Myeloproliferative Neoplasms
SHORT DESCRIPTION
Small molecule inhibitors of Pleckstrin-2 (Plek2) for treating cell proliferative diseases and disorders, particularly myeloproliferative neoplasms (MPNs).
NU Tech IDs: NU 2018-169, NU 2021-005
PRINCIPAL INVESTIGATOR
Peng Ji
Northwestern University Feinberg School of Medicine, Department of Pathology
IP...
Published: 5/27/2026
|
Updated: 5/27/2026
|
Inventor(s):
Keywords(s): Breast cancer, Cancer/Oncology, Colon cancer, Leukemia, Lung cancer, Pancreatic cancer, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Use of Nucleotide Synthesis Inhibitors for Targeted Therapy in MLL3/4 COMPASS Mutant Cancer
NU 2022-053
INVENTORS
Ali Shilatifard (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
Zibo Zhao (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
SHORT DESCRIPTION
A therapeutic platform that targets MLL3/4 COMPASS mutant cancers by using nucleotide synthesis inhibitors to disrupt...
Published: 5/26/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s): Bladder cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Leukemia, Lung cancer, Lymphoma, Prostate cancer, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Selective DOT1L Protein Degraders for Precision Cancer Therapy
NU 2022-081
INVENTORS
Sarki Abdulkadir (PI)*
Northwestern University Feinberg School of Medicine, Department of Urology
Gary Schiltz (PI)*
Weinberg College of Arts and Sciences, Department of Chemistry
SHORT DESCRIPTION
A small molecule PROTAC technology that degrades DOT1L protein for targeted treatment of leukemia and prostate...
Published: 5/13/2026
|
Updated: 2/3/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Cancer/Oncology, Leukemia, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
New Therapeutic Approach for the Treatment of Acute Myeloid Leukemia
NU 2017-214
Inventors
Ali Shilatifard*
Zibo Zhao
Short Description
A new therapeutic approach for the treatment of acute myeloid leukemia using casein kinase inhibitors.
Background
Leukemia is a group of cancers that affects the bone marrow and results in the overproduction of dysfunctional white blood cells (WBCs). The mixed lineage leukemia...
Published: 3/31/2026
|
Updated: 11/18/2025
|
Inventor(s):
Keywords(s): Cancer/Oncology, Leukemia, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Small Molecule Inhibitors of BAP1 for Cancer Therapy
NU 2019-130
PRIMARY INVENTOR
Ali Shilatifard
SHORT DESCRIPTION
A series of small molecule compounds targeting the BAP1 complex for the treatment of leukemia.
BACKGROUND
ASXL1, which encodes a core component of the BAP1 histone H2A deubiquitinase complex, is one of the most frequently mutated genes in malignant myeloid diseases. Mutations of ASXL1...
Published: 3/31/2026
|
Updated: 2/15/2022
|
Inventor(s):
Keywords(s): Biomedical, Cancer/Oncology, Leukemia, Small molecule
Category(s): Life Sciences > Therapeutics
|